share_log

Avenue Therapeutics | UPLOAD: Others

SEC announcement ·  May 9 00:46
Summary by Futu AI
Avenue Therapeutics, Inc. has been informed by the Division of Corporation Finance Office of Life Sciences that the United States Securities and Exchange Commission (SEC) will not review the company's Registration Statement on Form S-3, which was filed on May 6, 2024. The SEC's communication, dated May 8, 2024, was addressed to Dr. Alexandra MacLean, CEO of Avenue Therapeutics. The SEC also reminded the company of its responsibility for the accuracy and adequacy of disclosures, irrespective of the SEC's review process. The SEC provided contact information for any further questions and referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process.
Avenue Therapeutics, Inc. has been informed by the Division of Corporation Finance Office of Life Sciences that the United States Securities and Exchange Commission (SEC) will not review the company's Registration Statement on Form S-3, which was filed on May 6, 2024. The SEC's communication, dated May 8, 2024, was addressed to Dr. Alexandra MacLean, CEO of Avenue Therapeutics. The SEC also reminded the company of its responsibility for the accuracy and adequacy of disclosures, irrespective of the SEC's review process. The SEC provided contact information for any further questions and referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.